Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis Leukemia (2004) Imatinib mesylate produces complete hematologic and cytogenetic remissions in chronic myeloid leukemia (CML) by effectively inhibiting the resident BCR/ABL oncoprotein. 1 More recently, the drug was also shown to be active in eosinophilic and mast cell disorders in the absence of the bcr/abl mutation. 2, 3 The drug target in the latter disorders was subsequently discovered to be an activating mutation of the platelet-derived growth factor receptor-a gene (FIP1L1-PDGFRA). 4, 5 In the current case report, we demonstrate a morphologic as well as immunophenotypic normalization of bone marrow mast cells in a patient with eosinophilia-associated systemic mastocytosis treated with imatinib mesylate.
A 30-year-old male presented with a 5-month history of fatigue, fever, night sweat and 20 kg weight loss. He was found to have splenomegaly, anemia and leukocytosis of 30 Â 10 9 /l with 16% eosinophils. Bone marrow aspirate and biopsy performed elsewhere were reported as being consistent with a myeloproliferative disorder. Stool and blood tests were negative for bacterial or parasitic infection. Electrocardiogram and echocardiogram were normal and there was no evidence of end-organ disease. Subsequent follow-up demonstrated progressive splenomegaly (6 cm below the left costal margin) and worsening anemia (hemoglobin was 7.7 g/dl) with a dramatic peripheral leukocytosis to 140 Â 10 9 /l with 14% eosinophils and 2% blasts. He was managed elsewhere with transfusions and a prolonged course of hydroxyurea therapy at 3 g/day. Allogeneic bone marrow transplantation was considered, but typing of his seven siblings failed to identify a donor. Profound hydroxyurea-induced pancytopenia led to transfer to our institution. Bone marrow biopsy at our institution led to the diagnosis of systemic mastocytosis with associated eosinophilia. The BM was markedly hypercellular (95% cellularity) with aggregates of atypical mast cell infiltrates (15% involvement) associated with intense eosinophilia, monocytosis and left-shifted granulopoiesis ( Figure 1a ). Immunohistochemical staining demonstrated aggregates of c-Kit (CD117)-and tryptase-positive atypical mast cells in a perivascular location. Flow cytometry revealed that the bone marrow mast cells coexpressed CD117 and CD25 but not CD2 (Figure 1c) . Bone marrow cytogenetic studies and fluorescent in situ hybridization (FISH) for bcr/abl were negative. PCR analysis for c-kit mutations (D816 V and V569G) were negative.
After failing an initial treatment trial with interferon-a, a therapeutic trial with imatinib mesylate at the dose of 400 mg/ day was initiated based on our previous successful experience with the treatment of bcr/abl-negative hypereosinophilic syndrome. 2 Within 2 days, the leukocyte count decreased from 69.8 Â 10 9 to 9.4 Â 10 9 /l and the platelet count remained stable at 31 Â 10 9 /l. After 5 days, the leukocyte count was at 3.2 Â 10 9 /l with an absolute neutrophil count of 1670, an absolute eosinophil count (AEC) of below 0.1 Â 10 9 /l, and a stable platelet count. The dose of imatinib was reduced to 100 mg daily after 1 week of therapy. Within 4, 5 and 6 weeks, the platelet, neutrophil and hemoglobin normalized, respectively, and the patient achieved complete clinical remission. A bone marrow biopsy after 3 months of imatinib therapy revealed normal histology (Figure 1b) and a marked reduction (from 15% involvement to minimal evidence of morphologically abnormal mast cells) in the previously dominant aberrant CD25-positive mast cell population (Figure 1d) . The AEC at that point was below 0.2 Â 10 9 /l. The patient remains in complete remission at last follow-up (19 months) and laboratory studies on archival tissue confirmed the presence of the FIP1-PDGFRA oncogenic mutation that is targeted by imatinib mesylate. 4 The current communication is the first to describe immunophenotypic normalization of bone marrow mast cells in patients with systemic mastocytosis treated with imatinib mesylate. It is to be recalled that neoplastic mast cells are both morphologically (spindle-shaped and hypogranular vs round with abundant cytoplasmic granules) and immunophenotypically (CD117 þ / CD25 þ vs CD117 þ /CD25 À ) different from their normal as well as reactive counterparts. 6 The current case demonstrates the value of bone marrow histology enhanced with tryptase or CD117-based immunohistochemistry as well as bone marrow mast cell immunophenotyping in the monitoring of effective therapy in systemic mastocytosis. The emergence of novel chromosomal aberrations in Ph (À) cells of chronic myelogenous leukemia (CML) patients treated with interferon-alpha (IFN-alpha) is a rare event; a recent review of the literature identified 10 such cases. [1] [2] In most CML patients, treatment with imatinib mesylate (Glivec), a specific ABL kinase inhibitor, leads to disappearance of the Ph chromosome; nevertheless, the long-term efficacy and toxicity profile of imatinib remain largely unknown. Intriguingly, over the last 2 years, several groups have demonstrated Ph (À) cytogenetically abnormal clones in patients with CML treated with imatinib, at a rate seemingly higher than the one observed with IFN-alpha. [2] [3] [4] [5] [6] [7] [8] In our department, in a cohort of 35 CML patients treated with imatinib for a median duration of 16.0 months (range, 3-42 months), three patients developed novel chromosomal aberrations in Ph (À) cells as reported below.
Case 1
A 22-year-old male was diagnosed with CML in accelerated phase in December 2001. Cytogenetic analysis of bone marrow (BM) mononuclear cells revealed t(9;22) (q34;q11) in all metaphases tested. RT-PCR identified b3a2 chimeric BCR-ABL mRNA transcripts. The patient was initially given hydroxyurea; starting from March 2002, he was put on imatinib at 400 mg/ day. At 6 months on imatinib, he had attained complete hematological remission and a minimal cytogenetic response with 96% Ph( þ ) metaphases. Imatinib dose was then increased to 600 mg/day; at 14 months, cytogenetic analysis demonstrated major cytogenetic response (25.9% (7/27) Ph ( þ ) metaphases) concurrently with the appearance of a novel hypodiploid clone with monosomy 7 in 8/27 metaphases, all Ph (À); interestingly, there was also a Ph (À) metaphase with trisomy 8. FISH analysis confirmed isolated trisomy 8 and monosomy 7 in 6.5 and 29% of cells, respectively. Examination of BM aspirate and biopsy samples showed no evidence of myelodysplasia. The patient underwent allogeneic matched sibling hematopoietic cell transplantation in July 2003; he remains in complete hematological, cytogenetic and molecular remission.
Case 2
A 43-year-old female subject was diagnosed with CML in myeloid blast crisis (10% MPO þ CD34 þ BM blast cells;
